Mizuho Cuts LivaNova (NASDAQ:LIVN) Price Target to $70.00

LivaNova (NASDAQ:LIVN) had its price target cut by investment analysts at Mizuho from $80.00 to $70.00 in a research note issued to investors on Thursday, Benzinga reports. The firm currently has an “outperform” rating on the stock. Mizuho’s target price would suggest a potential upside of 36.91% from the stock’s previous close.

LIVN has been the topic of a number of other reports. Stifel Nicolaus boosted their price objective on LivaNova from $70.00 to $72.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. Needham & Company LLC restated a “buy” rating and set a $75.00 price objective on shares of LivaNova in a research report on Thursday. The Goldman Sachs Group started coverage on LivaNova in a research note on Friday, October 4th. They issued a “buy” rating and a $65.00 target price for the company. Baird R W upgraded shares of LivaNova from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 17th. Finally, Robert W. Baird lifted their target price on shares of LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a research note on Thursday. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $69.17.

LivaNova Price Performance

LIVN opened at $51.13 on Thursday. LivaNova has a fifty-two week low of $42.75 and a fifty-two week high of $64.47. The firm has a 50-day moving average of $51.13 and a 200 day moving average of $53.12. The firm has a market cap of $2.78 billion, a P/E ratio of 121.74 and a beta of 1.00. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.94 and a current ratio of 3.37.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings data on Wednesday, July 31st. The company reported $0.81 earnings per share for the quarter, topping the consensus estimate of $0.66 by $0.15. LivaNova had a return on equity of 13.81% and a net margin of 1.91%. The company had revenue of $318.60 million during the quarter, compared to analyst estimates of $305.05 million. On average, research analysts expect that LivaNova will post 2.58 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Arizona State Retirement System lifted its holdings in shares of LivaNova by 2.0% during the second quarter. Arizona State Retirement System now owns 15,104 shares of the company’s stock valued at $828,000 after purchasing an additional 299 shares during the last quarter. State of Michigan Retirement System grew its stake in shares of LivaNova by 2.3% during the 1st quarter. State of Michigan Retirement System now owns 13,211 shares of the company’s stock valued at $739,000 after purchasing an additional 300 shares during the period. Atria Investments Inc increased its holdings in LivaNova by 6.2% during the third quarter. Atria Investments Inc now owns 5,653 shares of the company’s stock valued at $297,000 after buying an additional 331 shares during the last quarter. Fifth Third Bancorp raised its holdings in LivaNova by 97.1% in the 2nd quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock worth $37,000 after purchasing an additional 332 shares during the period. Finally, Hexagon Capital Partners LLC raised its stake in LivaNova by 117.8% during the 2nd quarter. Hexagon Capital Partners LLC now owns 684 shares of the company’s stock worth $37,000 after acquiring an additional 370 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.